Company news
Beone Medicines Ltd. Class A (SSE:688235) news
Every Beone Medicines Ltd. Class A press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
"BEONE MEDICINES LTD."Announcement on Voluntary Disclosure of Adjustment of Operating Performance Forecast for 2026
August 5, 2026
"BEONE MEDICINES LTD."Announcement on Voluntary Disclosure of Holding Conference Call for Company Performance
July 17, 2026
"BEONE MEDICINES LTD."Grant of Restricted Share Units
July 8, 2026
"BEONE MEDICINES LTD."Voluntary Announcement on Progress of Clinical Trial of BRUKINSA (Zanubrutinib Capsules)
June 30, 2026
Announcement on the Handling of Relevant Tax Matters
June 26, 2026
Indicative Announcement on Change in Equity of Shareholders with Over 5% Shares Reaching 1% Scale
June 1, 2026
BeOne Medicines’ BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma
May 13, 2026
Report for Q1 2026
May 11, 2026
BeOne Medicines Announces First Quarter 2026 Financial Results and Business Updates
May 6, 2026
U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA
April 29, 2026
Announcement on the Record Date for Shareholders' Registration for the 2026 Annual General Meeting
April 28, 2026
Announcement on Signing of Cooperation Agreement and Related Party Transactions
April 27, 2026
BeOne Medicines to Announce First Quarter 2026 Financial Results on May 6
April 22, 2026
Announcement on Realizing Profitability for the 1st Time and Canceling Stock Abbreviation U
April 14, 2026
Announcement on Convening the 2025 Annual Performance Briefing
April 8, 2026
Announcement on Renewing Engagement of Audit Institution for 2026
March 25, 2026
BeOne Medicines Announces Fourth Quarter and Full Year 2025 Financial Results, Highlighting Global Success of BRUKINSA and Foundational O...
February 26, 2026
BeOne Medicines to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26
February 11, 2026
BeOne Medicines Highlights Global Oncology Leadership at 44th Annual J.P. Morgan Healthcare Conference
January 13, 2026
ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA
January 6, 2026
BeOne Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference
December 23, 2025
BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma
December 18, 2025
BRUKINSA Delivers Landmark 74% 6-Year PFS in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia
December 8, 2025
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies
December 7, 2025
U.S. FDA Grants Priority Review to Sonrotoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
November 26, 2025
BeOne Medicines Showcases Leadership in B-cell Malignancies at ASH 2025
November 20, 2025
Positive Phase 3 Results Support ZIIHERA® as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA® and Chemotherapy as New Stand...
November 17, 2025
Report for Q3 2025
November 12, 2025
BeOne Medicines Announces Third Quarter 2025 Financial Results and Business Updates
November 6, 2025
BeOne Medicines to Present at Upcoming Investor Conferences
October 28, 2025
BeOne Medicines to Announce Third Quarter 2025 Financial Results on November 6
October 22, 2025
BeOne Medicines Presents New Data on TEVIMBRA in Lung Cancer at ESMO 2025
October 20, 2025
BeOne Medicines’ Sonrotoclax Granted Breakthrough Therapy Designation by U.S. FDA
October 13, 2025
Announcement on Progress in Litigation Involving the Company
October 8, 2025
Announcement on Abnormal Fluctuations in Stock Trading
September 2, 2025
BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)
August 29, 2025
European Commission Approves TEVIMBRA® as Neoadjuvant/Adjuvant NSCLC Treatment Ahead of Late-Breaking Data Presentation at WCLC 2025
August 27, 2025
BeOne to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
August 26, 2025
BeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 Million
August 25, 2025
Announcement on Convening the 2025 Semi-annual Performance Briefing
August 22, 2025
European Commission Approves Tablet Formulation of BeOne Medicines’ BRUKINSA® for All Approved Indications
August 21, 2025
Indicative Announcement on Change in Equity of Shareholders with Over 5% Shares Reaching 1%
August 20, 2025
BeOne Medicines Announces Second Quarter 2025 Financial Results and Business Updates
August 6, 2025
BeOne Medicines Receives PRIME Designation from the European Medicines Agency for BGB-16673 in Waldenstrom’s Macroglobulinemia
July 31, 2025
BeOne Medicines Receives Positive CHMP Opinion for TEVIMBRA® in Neoadjuvant/Adjuvant NSCLC Treatment
July 28, 2025
BeOne Medicines to Announce Second Quarter 2025 Financial Results on August 6
July 16, 2025
European Commission Approves TEVIMBRA® in Combination with Chemotherapy as a First-Line Treatment for Nasopharyngeal Carcinoma
July 10, 2025
BeOne Medicines Showcases Groundbreaking Oncology Pipeline at R&D Day
June 26, 2025
BeOne Medicines Receives Positive CHMP Opinion for Tablet Formulation of BRUKINSA®
June 25, 2025
BeOne Medicines Showcases Breakthrough Data in CLL and MCL at EHA 2025
June 12, 2025